Compare Ginkgo Bioworks Holdings Inc (DNA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Merck & Co., Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Merck & Co., Inc. trades at $123.5 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 505.2× Ginkgo Bioworks Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MRK | |
|---|---|---|
Market Cap | $590.53M | $298.31B |
Sector | Health | Health |
52-Week High | $16.14 | $129.52 |
52-Week Low | $5.48 | $77.60 |
Enterprise Value | $627.78M | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Merck (MRK) trades at $124.03, up 0.4% on the day, with a bullish technical signal and strong analyst support. The company reported solid earnings beats in recent quarters, including Q1 2026's better-than-expected loss, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth efforts amid competitive pressures.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include patent expirations and rising debt. With a consensus price target of $137.30 offering ~11% upside, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic and regulatory headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
